Emerging treatments

The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma. Ma H et al. Acta Oncol. 2017 Aug 22:1-7. doi: 10.1080/0284186X.2017.1364868. [Epub ahead of print]. Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. Popat R et al. Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14897. [Epub ahead of…

Details

Diagnostic techniques and prognostic indicators

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Hillengass J et al. Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Mills JR et al. Blood Cancer J. 2017 Aug 25;7(8):e590. doi: 10.1038/bcj.2017.75. Evaluation of pretreatment red cell distribution…

Details

Current treatments

Results of Prospective Randomized, Open Label, Non -Inferiority Study of Tbo-Filgrastim (Granix®) Versus Filgrastim (Neupogen®) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non -Hodgkin Lymphoma. Bhamidipati PK et al. Biol Blood Marrow Transplant. 2017 Aug 7. pii: S1083-8791(17)30619-5. doi: 10.1016/j.bbmt.2017.07.023. [Epub ahead of print]. Multiple myeloma with extramedullary disease: impact of autologous stem…

Details

Complications of myeloma and its treatments

Uterine Extramedullary Plasmacytoma as a Primary Manifestation of Multiple Myeloma. Codorniz A et al. Rev Bras Ginecol Obstet. 2017 Aug 23. doi: 10.1055/s-0037-1605373. [Epub ahead of print]. Autoimmune HIT due to apheresis catheter heparin flushes for stem-cell harvesting before autotransplantation for myeloma. Mian H et al. Blood. 2017 Aug 22. pii: blood-2017-06-788679. doi: 10.1182/blood-2017-06-788679. [Epub ahead of print]. Infectious complications in multiple myeloma receiving autologous…

Details

Biology and genetics

Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall. Tenreiro MM et al. Angiogenesis. 2017 Aug 24. doi: 10.1007/s10456-017-9571-8. [Epub ahead of print]. Intracellular light chain crystals in myeloma. Staubach ZG et al. Blood. 2017 Aug 24;130(8):1070. doi: 10.1182/blood-2017-04-779207. Logic programming reveals alteration of key transcription factors in multiple myeloma. Miannay B et al. Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9. Oncolytic…

Details

Genmab report positive results from Phase III daratumumab trial for myeloma patients

The Danish biotechnology company, Genmab, have announced that the Phase III trial, ALCYONE, has achieved its primary endpoint of improving progression-free survival in newly diagnosed myeloma patients. This study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone. Treatment including daratumumab was demonstrated to reduce the risk of disease…

Details

Carfilzomib combination approved for use in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared…

Details

Lenalidomide maintenance treatment demonstrates significant overall survival benefit following HDT-ASCT

Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…

Details